Log in to search using one of your social media accounts:

 

Aerie submits second drug for FDA approval
Aerie Pharmaceuticals has submitted its second glaucoma drug, Roclatan, to the U.S. Food and Drug Administration for potential approval. Aerie said Tuesday that it expects the FDA review period for Roclatan to be just 10 months rather than the typical 12 months because Roclatan is a fixed-dose combination of two drugs previously approved in the U.S. The move follows the commercial launch of its first drug approved by the FDA, know n as Rhopressa. The FDA approved that drug in December – two months… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - May 15, 2018 Category: American Health Authors: Jennifer Henderson Source Type: news

Butterfly wing inspires design of glaucoma sensor
Inspired by a clear butterfly wing, researchers designed a tiny implantable sensor to measure eye pressure. With further development, it could be tested in people. (Source: NIH Research Matters from the National Institutes of Health (NIH))
Source: NIH Research Matters from the National Institutes of Health (NIH) - May 15, 2018 Category: Consumer Health News Source Type: news

The keto diet protects your eyesight
To so-called keto diet has shown to ease seizures in epilepsy patients. Now a study has found the slimming celebrity diet could also lower the risk of glaucoma, the leading cause of blindness. (Source: the Mail online | Health)
Source: the Mail online | Health - May 14, 2018 Category: Consumer Health News Source Type: news

Locations, circumstances, and outcomes of falls in patients with glaucoma - Sotimehin AE, Yonge AV, Mihailovic A, West SK, Friedman DS, Gitlin LN, Ramulu PY.
PURPOSE: To characterize the locations, circumstances, and outcomes of falls in patients with varying degrees of glaucoma. DESIGN: Prospective cohort study METHODS: Patients with suspected or diagnosed glaucoma completed monthly calendars reporting... (Source: SafetyLit)
Source: SafetyLit - May 14, 2018 Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news

Glaucoma Device Makers See a Bright Future Ahead
Were The Graduate's Ben Braddock to receive a one-word bit of career advice today, it might very well be "MIGS" instead of plastics. MIGS stands for minimally invasive glaucoma surgery, and both financial analysts and developers of the tiny devices designed to treat the disease expect the market to pop for the foreseeable future. "On a scale of one through 10, I would say the market is probably somewhere between one and two in terms of maturity," said Dave Van Meter, CEO of Irvine, CA-based Ivantis. "The market in the U.S. today is probably somewhere around a couple hundred million dollars, ac...
Source: MDDI - May 11, 2018 Category: Medical Devices Authors: Greg Goth Tags: Implants Source Type: news

With $334M in cash, Aerie preps to break even
With $334 million in cash, equivalents and investments as of March 31 and its first drug launched, Durham ’s Aerie Pharmaceuticals is prepped to break even. The company (Nasdaq: AERI) confirmed Tuesday that its current cash is sufficient to get it to its break-even point on its first quarter financial results call. After hiring and training a 100-person sales force, Aerie’s glaucoma drug Rhopressa officially launched last week in national and regional pharmaceutical distributors in the U.S. “We… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - May 9, 2018 Category: Health Management Authors: Jennifer Henderson Source Type: news

With $334M in cash, Aerie preps to break even
With $334 million in cash, equivalents and investments as of March 31 and its first drug launched, Durham ’s Aerie Pharmaceuticals is prepped to break even. The company (Nasdaq: AERI) confirmed Tuesday that its current cash is sufficient to get it to its break-even point on its first quarter financial results call. After hiring and training a 100-person sales force, Aerie’s glaucoma drug Rhopressa officially launched last week in national and regional pharmaceutical distributors in the U.S. “We… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - May 9, 2018 Category: Biotechnology Authors: Jennifer Henderson Source Type: news

Aerie launches glaucoma drug in U.S.
Aerie Pharmaceuticals (NSDQ:AERI) today launched its once-daily eye-drop product, Rhopressa, which is designed to reduce intraocular pressure in patients with glaucoma or ocular hypertension. The Durham, N.C.-based company won FDA approval for Rhopressa in December last year, two months before the agency was expected to make a decision. Get the full story at our sister site, Drug Delivery Business News. The post Aerie launches glaucoma drug in U.S. appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - April 30, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Optical/Ophthalmic Pharmaceuticals Wall Street Beat Aerie Pharmaceuticals Source Type: news

UMKC lands $1.97M grant for glaucoma treatment
Researchers at the University of Missouri-Kansas City School of Medicine landed $1.937 million to develop a way to treat patients with end-stage glaucoma. The five-year grant from the National Institutes of Health will support principal investigator Karl Kador's research on ways to restore vision to patients with glaucoma and other eye disorders. Kador, an assistant professor of ophthalmology and biomedical sciences, studies disease and injuries that lead to the death of retinal ganglion cells,… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - April 26, 2018 Category: American Health Authors: Elise Reuter Source Type: news

French pharma moves U.S. base to RTP from Texas
French pharmaceutical company Nicox has opened its new U.S. development office in Research Triangle Park, moving it from Fort Worth, Texas. The opening of the office comes as Nicox is looking to begin phase 2 clinical studies of product candidates for glaucoma and blepharitis – an inflammation of the eyelid. In the Triangle area, Nicox was able to hire all of the team members it needed to get started within a month, says Gavin Spen cer, executive vice president and chief business officer. The… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - April 25, 2018 Category: American Health Authors: Jennifer Henderson Source Type: news

French pharma moves U.S. base to RTP from Texas
French pharmaceutical company Nicox has opened its new U.S. development office in Research Triangle Park, moving it from Fort Worth, Texas. The opening of the office comes as Nicox is looking to begin phase 2 clinical studies of product candidates for glaucoma and blepharitis – an inflammation of the eyelid. In the Triangle area, Nicox was able to hire all of the team members it needed to get started within a month, says Gavin Spen cer, executive vice president and chief business officer. The… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - April 25, 2018 Category: Biotechnology Authors: Jennifer Henderson Source Type: news

Report: Johnson & Johnson sees Vision Care biz grow, looks to expand beyond contacts
Johnson & Johnson (NYSE:JNJ) saw its vision care sales grow 34% last quarter over its previous first quarter as it looks to significantly grow the business into the surgical and device segments, according to a CNBC report. The company added a number of surgical products alongside a contact subscription service, which come in addition to its existing popular Acuvue contact lens line, according to the report. The investment has seen a significant return for the company, becoming one of its fastest-growing platforms. Johnson & Johnson only began investing in eye surgery two years ago after announcing it would acq...
Source: Mass Device - April 23, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Optical/Ophthalmic Wall Street Beat johnsonandjohnson Source Type: news

Ivantis touts 1-year head-to-head Hydrus, iStent study data
This study looks at the viability of MIGS in patients who don’t need or may have already had cataract surgery, so it’s a vital addition to our growing body of evidence supporting MIGS,” Compare trial medical monitor Dr. Iqbal Ahmed said in a prepared release. Ivantis said the 152-patient trial was the first to compare two minimally invasive glaucoma surgery device for treating open-angle glaucoma in a standalone procedure. The study aimed to compare safety and effectiveness of both devices in lowering IOP and reducing eye-drop medication. Results at one year showed that 47% of eyes treated with the Hydrus...
Source: Mass Device - April 16, 2018 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Optical/Ophthalmic Glaukos Ivantis Source Type: news

Glaukos touts 2-year iStent inject pivotal trial data, levies infringement suit against Ivantis
Glaukos (NYSE:GKOS) today released two-year data from the FDA investigational device exemption pivotal trial of its iStent inject trabecular micro-bypass system, and announced a patent infringement suit it filed against Ivantis. Results of the 505-patient study were presented at the American Society of Cataracts and Refractive Surgery annual meeting by Dr. Thomas Samuelson of the Minnesota Eye Consultants, the San Clemente, Calif.-based company said. The iStent inject trabecular micro-bypass system is designed to treat mild-to-moderate open-angle glaucoma in patients undergoing cataract surgery. It uses a pa...
Source: Mass Device - April 16, 2018 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Optical/Ophthalmic Patent Infringement Glaukos Source Type: news

Health Tip: Using Glaucoma Eye Drops
-- Eye drops are a popular way to treat glaucoma, a group of diseases that, if untreated, can damage the optic nerve and lead to blindness. To be safe and effective, however, these eye drops must be used as prescribed by a doctor. The U.S. National... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 13, 2018 Category: General Medicine Source Type: news

Health Tip: Using Glaucoma Eye Drops
Title: Health Tip: Using Glaucoma Eye DropsCategory: Health NewsCreated: 4/13/2018 12:00:00 AMLast Editorial Review: 4/13/2018 12:00:00 AM (Source: MedicineNet Eyesight General)
Source: MedicineNet Eyesight General - April 13, 2018 Category: Opthalmology Source Type: news

New glaucoma treatment could ease symptoms while you sleep
(University of British Columbia) Eye drops developed by UBC researchers could one day treat glaucoma while you sleep -- helping to heal a condition that is one of the leading causes of blindness around the world. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - April 11, 2018 Category: Biology Source Type: news

RTP company lands $5.7M for glaucoma work
A Research Triangle Park-based pharmaceutical company has landed $5.7 million from several investors. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - April 10, 2018 Category: American Health Authors: Jennifer Henderson Source Type: news

Gait parameters, functional mobility and fall risk in individuals with early to moderate primary open angle glaucoma: a cross-sectional study - Gomes HA, Moreira BS, Sampaio RF, Furtado SRC, Cronemberger S, Gomes RA, Kirkwood RN.
This study investigated the influence of early to moderate primary open angle glaucoma on gait, functional mobility and fall risk. METHODS: Thirty-three participants in the early and moderate stages of primary open angle glaucoma and 34 ... (Source: SafetyLit)
Source: SafetyLit - April 10, 2018 Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news

Scanning behaviour and daytime driving performance of older adults with glaucoma - Lee SS, Black AA, Wood JM.
PURPOSE: To assess the link between visual scanning behaviour and closed-road driving performance in older drivers with glaucomatous visual impairment. METHODS: Participants included 13 older drivers with glaucoma (mean age=72.0 ±6.7▒y; average b... (Source: SafetyLit)
Source: SafetyLit - April 7, 2018 Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news

NTU Singapore and SERI invent new scope to diagnose glaucoma
(Nanyang Technological University) A new 'pen camera' has been developed jointly by scientists from Nanyang Technological University, Singapore (NTU Singapore) and the Singapore Eye Research Institute (SERI) to diagnose the glaucoma type in a cheaper, more efficient manner. Currently, an eye specialist has to press a glass scope against a patient's eye to make a diagnosis. As this process is time-consuming and requires a skilled eye specialist, it is not done as often as required during eye checks. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - April 5, 2018 Category: International Medicine & Public Health Source Type: news

Glaucoma symptoms: Red eyes and headaches could be early warning signs of the disease
RED EYES and headaches could be early signs of glaucoma, the eye condition that can cause vision loss. Other symptoms include blurred vision or seeing halos around lights. (Source: Daily Express - Health)
Source: Daily Express - Health - March 28, 2018 Category: Consumer Health News Source Type: news

Review of the Xen Gel Stent and InnFocus MicroShunt Review of the Xen Gel Stent and InnFocus MicroShunt
These new devices for subconjunctival glaucoma surgery show promising early clinical results in terms of safety and IOP reduction.Current Opinion in Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 27, 2018 Category: Consumer Health News Tags: Ophthalmology Journal Article Source Type: news

Pioneering glaucoma operation to drain excess eye fluid will 'save sight of thousands of patients'  
A pioneering procedure could prevent thousands of Britons with the eye condition glaucoma from losing their sight. The disease, which affects at least 600,000 people in Britain. (Source: the Mail online | Health)
Source: the Mail online | Health - March 25, 2018 Category: Consumer Health News Source Type: news

Maintaining Independence with Vision Rehabilitation
Treatment TermsLow vision rehabilitation Author Erin Hull Overview Verdina Gillette-Simms was only 18 when she was diagnosed with glaucoma. Over time, the elevated eye pressure associated with the disease damaged her optic nerve and left her struggling to see clearly. Now 56, Gillette-Simms considers herself fortunate. She's been able to maintain her independence thanks to the low-vision tools and techniques she learned at the Duke Eye Center's low-vision rehabilitation program. Preview Image Content Blocks Header Living with Glaucoma Content" Every day is a different day, " said Gillette-Simms...
Source: dukehealth.org: Duke Health News - March 23, 2018 Category: Consumer Health News Authors: efh7 at duke.edu Source Type: news

Self-tonometry: Good Potential but Not Yet Practical Self-tonometry: Good Potential but Not Yet Practical
Self-measurement of IOP in patients with glaucoma has intriguing possibilities. But is it realistic?Medscape Optometry (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 23, 2018 Category: Consumer Health News Tags: None Viewpoint Source Type: news

City Council panel wants to develop workplace guidelines on medical marijuana
Here ’s the dilemma. Say you went through all the legal steps to get your medical marijuana card, and you take your legally acquired medical marijuana consistently to treat your glaucoma, or epilepsy, or PTSD. But, if your employer suspects you’re using marijuana, you can be drug tested. And if you fail, you can be fired. Cannabis is a schedule I drug under federal law, meaning it’s illegal. But under Pennsylvania law, medical marijuana is legal for patients with certain conditions. This puts… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - March 15, 2018 Category: American Health Authors: Anne Hoffman Source Type: news

South Africa:Gauteng Health Commemorates World Glaucoma Week, 11 to 17 Mar
[Govt of SA] As part of ongoing initiatives to create awareness on eye care and to reduce the number of people that go blind due to avoidable causes, the Gauteng Department of Health will host a marathon of activities in commemoration of World Glaucoma Week. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - March 14, 2018 Category: African Health Source Type: news

Drug delivering contact lenses win MIT ’s top healthcare innovation prize
[Image from MIT]Contact lenses that deliver medications directly to the eye over a period of days or weeks was the recent grand prize winner of Massachusetts Institute of Technology’s Sloan Healthcare Innovation Prize. The MIT Sloan Healthcare Innovation Prize competition had 8 finalists who pitched their healthcare innovations to judges from Optum and other local venture firms, as well as an audience in MIT’s Wong Auditorium. Harvard Medical School affiliate Theraoptix won a $25,000 grand prize in the competition. Strand Therapeutics took home the second place prize of $2,000 for developing mRNA-based cancer-f...
Source: Mass Device - March 12, 2018 Category: Medical Devices Authors: Danielle Kirsh Tags: Diagnostics Drug-Device Combinations Hospital Care Imaging mHealth (Mobile Health) Glaucoma Healthcare Hospitality Systems Iterative Scopes Kinematics Massachusetts Institute of Technology MedTech o2Map SurgiBox Theraoptix Umbu Source Type: news

Ask How Long Does it Take Blind from Glaucoma
How Long Does it Take to Go Blind from Glaucoma? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - March 9, 2018 Category: General Medicine Source Type: news

Ask What Is the First Sign of Glaucoma
What Is the First Sign of Glaucoma? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - March 9, 2018 Category: General Medicine Source Type: news

Do racial and gender disparities exist in newer glaucoma treatments?
(American Academy of Ophthalmology) The American Glaucoma Society today announced that it has awarded a grant to Mildred MG Olivier, MD, to study how often minimally invasive glaucoma surgery (MIGS) devices and procedures are used in black and Latino glaucoma patients and whether these devices perform similarly across races, ethnicities, genders, ages, and regions. The goal of Dr. Olivier's research is to increase quality care for glaucoma patients in all demographic groups. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 2, 2018 Category: International Medicine & Public Health Source Type: news

Ophthalmic device companies top The Street with Q4, FY2017 earnings
Ophthalmic device developers Glaukos (NYSE:GKOS) and Staar Surgical (NSDQ:STAA) this week posted fourth quarter and full fiscal year 2017 earnings that beat the streets, though only Glaukos has seen its shares rise in response. San Clemente, Calif.-based Glaukos posted profits of $1 million, or 3¢ per share, on sales of $41.7 million for the three months ended December 31, seeing the bottom-line grow 650.7% while sales grew 25.6% compared with the same period during the prior year. Earnings per share were ahead of the break-even consensus on Wall Street, where analysts were expecting to see sales of $40...
Source: Mass Device - March 1, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News MassDevice Earnings Roundup Wall Street Beat Glaukos STAAR Surgical Co Source Type: news

Update from the Dean – March 2018
A new PharmD curriculum; Implementing new practice opportunities for pharmacists; PharmD students shine in state and national clinical pharmacy competitions; A pioneer in pharmacogenomics; The NIH streak lives on; Improving adverse event reporting and medication therapy protocols; Big-data to cut drug discovery time; Computational approaches target dopamine receptors; Researchers expose industry manipulation of science by sugar industry; Women in science; Bioengineering devices to treat glaucoma, diabetes, kidney disease; Campus activism on... (Source: UCSF School of Pharmacy News)
Source: UCSF School of Pharmacy News - March 1, 2018 Category: Universities & Medical Training Authors: Paula Joyce Source Type: news

Complications of Micro-Invasive Glaucoma Surgery Complications of Micro-Invasive Glaucoma Surgery
Micro-invasive glaucoma surgery is becoming increasingly popular as an alternative to traditional glaucoma surgery, but are you aware of the potential complications associated with these procedures?Current Opinion in Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 27, 2018 Category: Consumer Health News Tags: Ophthalmology Journal Article Source Type: news

New directions found in understanding, fighting glaucoma
(Medical College of Georgia at Augusta University) Two distinctive handfuls of short molecules that regulate gene expression have been found in the eye fluid of patients with two distinct types of vision degenerating glaucoma. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 26, 2018 Category: International Medicine & Public Health Source Type: news

Glaucoma Drainage Devices Linked to Lower QOL
(MedPage Today) -- Timely diagnosis and preoperative discussions about potential psychosocial effects are key (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - February 24, 2018 Category: Primary Care Source Type: news

IDx Closer to Nod for Diabetic Retinopathy Diagnostic
Privately held IDx is developing an artificial intelligence-based system that could help with the diagnosis diabetic retinopathy – a disease that leads to blindness if undetected. The company met its endpoints in a pivotal trial of the IDx-DR system. The trial involved 900 diabetes patients at 10 sites. The study was designed to evaluate the diagnostic accuracy of the technology in detecting moderate to severe diabetic retinopathy, including macular edema. The results of the pivotal trial met the study hypotheses that were developed in consultation with FDA and demonstrated the IDx-DR system exceeded these performanc...
Source: MDDI - February 23, 2018 Category: Medical Devices Authors: Omar Ford Tags: Digital Health Medical Device Business Source Type: news

New glaucoma drugs yield large, lasting reductions in intraocular pressure
(Mary Ann Liebert, Inc./Genetic Engineering News) Two novel ocular hypotensive agents that have just been approved for use in humans -- netarsudil and latanoprostene bunod (LBN) -- greatly reduce intraocular pressure, with lasting results in various animal models of glaucoma and in humans. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 21, 2018 Category: International Medicine & Public Health Source Type: news

Factors associated with developing a fear of falling in subjects with primary open-angle glaucoma - Adachi S, Yuki K, Awano-Tanabe S, Ono T, Shiba D, Murata H, Asaoka R, Tsubota K.
BACKGROUND: To investigate the relationship between clinical risk factors, including visual field (VF) defects and visual acuity, and a fear of falling, among patients with primary open-angle glaucoma (POAG). METHODS: All participants answered the ... (Source: SafetyLit)
Source: SafetyLit - February 19, 2018 Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news

Guard Against Glaucoma: Ophthalmology Times
(MedPage Today) -- Also, understanding glaucoma on a cellular level (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - February 14, 2018 Category: Primary Care Source Type: news

Trabeculectomy After Failed Glaucoma Drainage Device Surgery Trabeculectomy After Failed Glaucoma Drainage Device Surgery
Is trabeculectomy a good option for patients with increased IOP after failure of glaucoma drainage device surgery?Medscape Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 13, 2018 Category: Consumer Health News Tags: Ophthalmology Viewpoint Source Type: news

Neutron study of glaucoma drugs offers clues about enzyme targets for aggressive cancers
(DOE/Oak Ridge National Laboratory) A team of researchers from ORNL's Energy and Transportation Science Division is using neutron imaging to study particulate filters that collect harmful emissions in vehicles. A better understanding of how heat treatments and oxidation methods can remove layers of soot and ash from these filters could lead to improved fuel-efficiency. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 12, 2018 Category: International Medicine & Public Health Source Type: news

Glaukos touts IOP, medication use reductions in iStent trial
Glaukos (NYSE:GKOS) today released results from a study of its iStent trabecular micro-bypass stent exploring its use during cataract surgery in patients with severe open-angle glaucoma, touting significant reductions in intraocular pressure and medication use. The San Clemente, Calif.-based company’s iStent micro-bypass stents are made from non-ferromagnetic titanium and coated in heparin, is designed to be implanted into multiple trabecular meshwork through a single corneal entry point to reduce IOP. Results were published in the January issue of the Journal of Glaucoma. “Although the iStent&nb...
Source: Mass Device - February 8, 2018 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Optical/Ophthalmic Glaukos Source Type: news

Could hiring 100 sales reps catapult revenue over $100M next year at Durham's Aerie Pharmaceuticals?
As Duke University spinout Aerie Pharmaceuticals plans to launch its first U.S. Food and Drug Administration-approved glaucoma product Rhopressa in the second quarter, its hiring of 100 sales representatives early this year could put sales soaring in 2019. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - February 8, 2018 Category: Biotechnology Authors: Jennifer Henderson Source Type: news

You Asked: Can Hanging Upside Down Relieve Back Pain?
If you’ve ever seen a TV commercial for inversion tables—those tilting contraptions that allow you to hang upside down by your ankles—and you suffer from back pain, you’ve probably been tempted to buy one. The ads claim that by dangling upside-down, bat-like, you’ll create separation between the vertebrae of your spine and neck. That separation supposedly reduces pressure on the nerves running between and around these vertebrae. You’ll relax tense muscles, and increase the flow of “nutrients” to the disks of your spine—all of which should help relieve back pain and prom...
Source: TIME: Health - February 7, 2018 Category: Consumer Health News Authors: Markham Heid Tags: Uncategorized Back Pain benefits of hanging upside down Exercise/Fitness healthytime inversion table inversion table therapy is hanging upside down good for you remedies for back pain what does an inversion table do yoga yoga headsta Source Type: news

The Growing Glaucoma Drug Landscape: Ophthalmology Times
(MedPage Today) -- Also, should we test new policies like we test new drugs? (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - February 7, 2018 Category: Primary Care Source Type: news

Second Sight touts 1st-in-human Orion cortical implant
Second Sight Medical (NSDQ:EYES) today announced the first trial implantation of its Orion cortical visual prosthesis system and updated on implantations of its Argus device and enrollment in an upcoming study. The first implantation procedure was performed late last month by Dr. Nader Pouratian at the Ronald Reagan UCLA Medical Center, the Sylmar, Calif.-based company said, as part of an FDA-cleared feasibility trial it won approval to launch last November. The Orion cortical visual prosthesis system is designed to convert images captured by a miniature video camera, mounted on a patient’s glasses, into a ...
Source: Mass Device - February 5, 2018 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Optical/Ophthalmic Second Sight Source Type: news

Should I Worry About This Telangiectasia?
Discussion Vascular stains are common problems that parents seek guidance about as they are often particularly worried that there may be an underlying problem or that it may be a long-term cosmetic problem. Fortunately many resolve or become less prominent or have treatment available. The term vascular stains includes all vascular malformations but commonly refers more directly to capillary malformations which are quite common. Some common vascular stains include: Nevus simplex Names: Angel’s kiss (glabella or forehead), salmon patch, stork bite (nape of neck), nevus roseus, fading macular stain Epidemiology: Very ...
Source: PediatricEducation.org - January 29, 2018 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

Innovation Lab eyes local professor as first incubator tenant
The University of Tennessee Health Science Center (UTHSC) has selected a local ophthalmology professor as the first user of its new Innovation Lab. Monica M. Jablonski, who works in UTHSC's College of Medicine, is developing a topical mixture that works better than standard eye drops and is working to improve treatments for conditions such as glaucoma and age-related macular degeneration. Jablonski and her company, OculoTherapy LLC, will ha ve access to the 420-square-foot space within the Memphis… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - January 24, 2018 Category: Pharmaceuticals Authors: Elle Perry Source Type: news